Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PARP inhibitor AZD2281

(... in-HIH-bih-ter ...)
A drug used alone or with other drugs to treat adults with certain types of prostate cancer, pancreatic cancer, breast cancer, or ovarian, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. PARP inhibitor AZD2281 blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitor AZD2281 is a type of PARP inhibitor. Also called AZD2281, Lynparza, and olaparib.
More Information
Search NCI's Dictionary of Cancer Terms